Advances in and applications of proteasome inhibitors

Current Opinion in Chemical Biology

Volumn 12, Issue 4, 2008, Pages 434-440

  Moore, Bradley S ^a,b   Eustáquio, Alessandra S ^a   McGlinchey, Ryan P ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA', BETA' EPOXYKETONE DERIVATIVE; BELACTOSINE A; BELACTOSINE C; BETA LACTONE; BORONIC ACID DERIVATIVE; BORTEZOMIB; CALPASTATIN; CEP 18770; CINNABARAMIDE; CINNABARAMIDE B; CINNABARAMIDE C; EPOXOMICIN; FELLUTAMIDE B; FLUOROSALINOSPORAMIDE; LACTACYSTIN; LACTACYSTIN BETA LACTONE; LEUPEPTIN; PR 171; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; SALINOSPORAMIDE B; SYRINGOLIN A; THREONINE; TMC 95; TMC 95A; UBIQUITIN; UCK 14; UNCLASSIFIED DRUG; VINYL SULFONE DERIVATIVE;

ACTINOBACTERIA; BIOLOGICAL ACTIVITY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG INDUSTRY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; GENE CLUSTER; HUMAN; MULTIPLE MYELOMA; NONHUMAN; PROTEIN DEGRADATION; REVIEW; STROKE; UNITED STATES;

DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 50449091498     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2008.06.033     Document Type: Review

References (44)

1. Goldberg A.L. Protein degradation and protection against misfolded or damaged proteins. Nature 426 (2003) 895-899
2. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4 (2004) 349-360
3. Goldberg A.L. Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. Biochem Soc Trans 35 (2007) 12-17. This refreshing review article by Alfred Goldberg shares his personal insight over the past 40 years on the discovery, function and clinical promise of the proteasome.
4. Orlowski R.Z., and Zeger E.L. Targeting the proteasome as a therapeutic strategy against haematological malignancies. Expert Opin Invest Drugs 15 (2006) 117-130
5. Orlowski R.Z., and Kuhn D.J. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14 (2008) 1649-1657
6. Zavrski I., Kleeberg L., Kaiser M., Fleissner C., Heider J., Sterz J., Jakob C., and Sezer O. Proteasome as an emerging therapeutic target in cancer. Curr Pharm Design 13 (2007) 471-485
7. Meiners S., Ludwig A., Stangl V., and Stangl K. Proteasome inhibitors: poisons and remedies. Med Res Rev 28 (2008) 309-327
8. Borissenko L., and Groll M. 20S proteasome and its inhibitors: crystallographic knowledge for drug development. Chem Rev 107 (2007) 687-717. This review article provides a comprehensive account of the proteasome and its inhibitors based on a structural perspective.
9. Vinitsky A., Michaud C., Powers J.C., and Orlowski M. Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex. Biochemistry 31 (1992) 9421-9428
10. Lowe J., Stock D., Jap B., Zwickl P., Baumeister W., and Huber R. Crystal structure of the 20S proteasome from the archaeon T. acidophilium at 3.4 Å resolution. Science 268 (1995) 533-539
11. Palmer J.T., Rasnick D., Klaus J.L., and Bromme D. Vinyl sulfones as mechanism-based cysteine protease inhibitors. J Med Chem 38 (1995) 3193-3196
12. Adams J., Behnke M., Chen S., Cruickshank A.A., Dick L.R., Grenier L., Klunder J.M., Ma Y.T., Plamondon L., and Stein R.L. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 8 (1998) 333-338
13. Meng L., Mohan R., Kwok B.H., Elofsson M., Sin N., and Crews C.M. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo anti-inflammatory activity. Proc Natl Acad Sci U S A 96 (1999) 10403-10408
14. Williamson M.J., Blank J.L., Bruzzese F.J., Cao Y., Daniels J.S., Dick L.R., Labutti J., Mazzola A.M., Patil A.D., Reimer C.L., et al. Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib. Mol Cancer Ther 5 (2006) 3052-3061
15. Dorsey B.D., Iqbal M., Chatterjee S., Menta E., Bernardini R., Bernareggi A., Cassara P.G., D'Arasmo G., Ferretti E., De Munari S., et al. Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer. J Med Chem 51 (2008) 1068-1072
16. Piva R., Ruggeri B., Williams M., Costa G., Tamagno I., Ferrero D., Giai V., Coscia M., Peola S., Massaia M., et al. CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 111 (2008) 2765-2775
17. Groll M., Kim K.B., Kairies N., Huber R., and Crews C.M. Crystal structure of epoxomycin:20S proteasome reveals a molecular basis for selectivity of α′,β′-epoxyketone proteasome inhibitors. J Am Chem Soc 122 (2000) 1237-1238
18. Demo S.D., Kirk C.J., Aujay M.A., Buchholz T.J., Dajee M., Ho M.N., Jiang J., Laidig G.J., Lewis E.R., Parlati F., et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 67 (2007) 6383-6391
19. Omura S., Matsuzaki K., Fujimoto T., Kosuge K., Furuya T., Fujita S., and Nakagawa A. Structure of lactacystin, a new microbial metabolite which induces differentiation of neuroblastoma cells. J Antibiot 44 (1991) 117-118
20. Fenteany G., Standaert R.F., Lane W.S., Choi S., Corey E.J., and Schreiber S.L. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 268 (1995) 726-731
21. Elliott P.J., Zollner T.M., and Boehncke W.H. Proteasome inhibition: a new anti-inflammatory strategy. J Mol Med 81 (2003) 235-245
22. Feling R.H., Buchanan G.O., Mincer T.J., Kauffman C.A., Jensen P.R., and Fenical W. Salinosporamide A, an antitumor proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora. Angew Chem Int Ed 115 (2003) 369-371
23. Macherla V.R., Mitchell S.S., Manam R.R., Reed K.A., Chao T.H., Nicholson B., Deyanat-Yazdi G., Mai B., Jensen P.R., Fenical W., et al. Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor. J Med Chem 48 (2005) 3684-3687
24. Williams P.G., Buchanan G.O., Feling R.H., Kauffman C.A., Jensen P.R., and Fenical W. New cytotoxic salinosporamides from the marine actinomycete Salinispora tropica. J Org Chem 70 (2005) 6196-6203
25. Reddy L.R., Fournier J.F., Reddy B.V.S., and Corey E.J. An efficient, stereocontrolled synthesis of a potent omuralide-salinosporin hybrid for selective proteasome inhibition. J Am Chem Soc 127 (2005) 8974-8976
26. McGlinchey R.P., Nett M., Eustaquio A.S., Asolkar R.N., Fenical W., and Moore B.S. Engineered biosynthesis of antiprotealide and other unnatural salinosporamide proteasome inhibitors. J Am Chem Soc 130 (2008) 7822-7823. Together with reference [27], this paper describes the engineered biosynthesis of diverse salinosporamide-based proteasome inhibitors.
27. Eustáquio A.S., and Moore B.S. Mutasynthesis of fluorosalinosporamide, a potent and reversible inhibitor of the proteasome. Angew Chem Int Ed 47 (2008) 3936-3938
28. Stadler M., Bitzer J., Mayer-Bartschmid A., Müller H., Benet-Buchholz J., Gantner F., Tichy H.-V., Reinemer P., and Baco K.B. Cinnabaramides A-G: analogues of lactacystin and salinosporamide from a terrestrial streptomycete. J Nat Prod 70 (2007) 246-252
29. Groll M., Larionov O.V., Huber R., and de Meijere A. Inhibitor-binding mode of homobelactosin C to proteasomes: New insights into class I MHC ligand generation. Proc Natl Acad Sci U S A 103 (2006) 4576-4579
30. Koguchi Y., Kohno J., Nishio M., Takahashi K., Okuda T., Ohnuki T., and Komatsubara S. TMC-95A, B, C, and D, novel proteasome inhibitors produced by Apiospora montagnei Sacc. TC 1093. Taxonomy, production, isolation and biological activities. J Antibiot 53 (2000) 105-109
31. Groll M., Gotz M., Kaiser M., Weyher E., and Moroder L. TMC-95-based inhibitor design provides evidence for the catalytic versatility of the proteasome. Chem Biol 13 (2006) 607-614
32. Udwary D.W., Zeigler L., Asolkar R.N., Singan V., Lapidus A., Fenical W., Jensen P.R., and Moore B.S. Genome sequencing reveals complex secondary metabolome in the marine actinomycete Salinispora tropica. Proc Natl Acad Sci U S A 104 (2007) 10376-10381
33. ®) at the molecular level. Knowledge gained herein could be used for the rational design of new agents.
34. Groll M., Huber R., and Potts B.C.M. Crystal structures of salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding. J Am Chem Soc 128 (2006) 5136-5141. Likewise, the molecular basis of proteasome inhibition by salinosporamide A, currently in human clinical trials, is discussed.
35. Chauhan D., Catley L., Li G.L., Podar K., Hideshima T., Velankar M., Mitsiades C., Mitsiades N., Yasui H., Letai A., et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 8 (2005) 407-419
36. Chauhan D., Hideshima T., and Anderson K.C. A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Br J Cancer 95 (2006) 961-965
37. Ahn K.S., Sethi G., Chao T.H., Neuteboom S.T.C., Chaturvedi M.M., Palladino M.A., Younes A., and Aggarwal B.B. Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappa B-regulated gene products. Blood 110 (2007) 2286-2295
38. Miller C.P., Ban K., Dujka M.E., McConkey D.J., Munsell M., Palladino M.A., and Chandra J. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemic cells. Blood 110 (2007) 267-277
39. Chauhan D., Singh A., Brahmandam M., Podar K., Hideshima T., Richardson P., Munshi N., Palladino M.A., and Anderson K.C. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood 111 (2008) 1654-1664
40. Groll M., Schellenberg B., Bachmann A.S., Archer C.R., Huber R., Powell T.K., Lindow S., Kaiser M., and Dudler R. A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism. Nature 452 (2008) 755-758. A new mechanism of proteasome inhibition involving the virulence factor syringolin A from the plant pathogen Pseudomonas syringie was recently described.
41. Hines J., Groll M., Fahnestock M., and Crews C.M. Proteasome inhibition by fellutamide A induces nerve growth factor synthesis. Chem Biol 15 (2008) 501-512. The discovery that fellutamide induces nerve growth factor secretion by a mechanism involving proteasome inhibition suggests new therapeutic applications by these inhibitors.
42. Landis-Piwowar K.R., Milacic V., Chen D., Yang H., Zhao Y., Chan T.H., Yan B., and Dou Q.P. The proteasome as a potential target for novel anticancer drugs and chemosensitizers. Drug Resist Updat 9 (2006) 263-273
43. Tsukamoto S., and Yokosawa H. Natural products inhibiting the ubiquitin-proteasome proteolytic pathway, a target for drug development. Curr Med Chem 13 (2006) 745-754
44. DeLano WL: The PyMOL Molecular Graphics System. http://www.pymol.org. 2002.